BACKGROUND: Patients with minor ischemic stroke (MIS) are frequently excluded from
thrombolytic therapy. Denial of therapy to these patients, however, remains controversial …

Background The dilemma of whether to treat mild strokes with tPA is a chronic problem. We
performed a meta-analysis and metaregression of the published literature to determine the …

Background and Purpose—The use of thrombolysis in acute minor ischemic stroke (MIS)
remains controversial. We sought to determine the safety and efficacy of intravenous tissue …

Objective To evaluate the outcomes of acute ischemic stroke patients with minor deficits
treated with either intravenous thrombolysis (IVT) or routine medical management (MM) …

Background: We evaluated the management, outcome and haemorrhagic risk in a cohort of
ischaemic stroke patients with mild symptoms treated with intravenous tissue plasminogen …

STUDY OBJECTIVE: Acute ischemic stroke patients eligible for tissue plasminogen activator
and with less severe neurologic deficits, although still generally benefiting from therapy, may …

The benefits and safety of intravenous recombinant tissue plasminogen activator (IV-tPA) for
patients with mild ischaemic stroke (MIS) are still unclear. The objective of this meta-analysis …

Intravenous (IV) tissue plasminogen activator (t-PA) is an effective medication currently used
to treat acute ischemic stroke within 3 hours of symptom onset in patients with an identifiable …

Aims The evidence of rt-PA intravenous thrombolysis in patients with minor ischemic stroke
(MIS) is still controversial. This study aims to investigate the effect of rt-PA intravenous …

Background and aims: The short time window is frequently cited as the main reason for
exclusion of intravenous tissue plasminogen activator (tPA) in acute stroke. Identifying and …